SAN FRANCISCO--(BUSINESS WIRE)--Jun 12, 2024-- Foresite Capital , a multi-stage healthcare and life sciences investment firm with more than $3.5 billion under management, announced today that it has closed its sixth fund with $900 million in capital commitments. With this new fund, Foresite Capital continues to invest in groundbreaking technologies, ranging from novel therapeutics to companies at the intersection of technology and biotechnology.
This press release features multimedia. View the full release here: https://www.businesswire.
com/news/home/20240612377413/en/ Foresite Capital managing directors (Photo: Business Wire) “ Fund VI is deploying capital into what I believe is one of the best biotech investment environments of my career,” said Jim Tananbaum , founder and CEO of Foresite Capital. “Advances in biology, genomics and artificial intelligence continue to converge. Biotech innovation is predicting, preventing and treating disease more effectively than ever before.
We believe these advances will lead to increasingly efficient investing at all stages.” Fund VI is investing in innovative, growth-oriented companies in three main areas: precision therapeutics, life science infrastructure, and healthcare delivery, including Alumis , CG Oncology , Latigo, RayThera and Xaira Therapeutics . Limited partners of Fund VI include a broad range of investors, among them university endowments, charitable foundations, medical institutions, pension funds, insurance compani.
